Labile Hypertension: Characteristics of a Referred Cohort
Matthew Elliott(Mayo Clinic in Florida), Jamie P. Dwyer(University of Utah), Jose M. Soto Soto(Mayo Clinic), William E. Haley(Jacksonville College), Peter M. Fitzpatrick(Jacksonville College)
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years
|JAMA|2016|1.2k
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189